Literature DB >> 16350414

In vitro assays of substrate degradation induced by high-risk HPV E6 oncoproteins.

Miranda Thomas1, Lawrence Banks.   

Abstract

The high-risk mucosal human papillomavirus E6 proteins were the first viral proteins that were shown to use the ubiquitin proteasome pathway for the inactivation of their cellular target proteins. The first substrate to be identified was the p53 tumor suppressor protein, and since then many other substrates for E6-induced degradation have been described. All of these require the presence of high-risk mucosal E6 together with the E1, E2, and E3 enzymes of the ubiquitin pathway. This activity of E6, although complex, is nonetheless amenable to in vitro analysis. Many different protocols have been described over the years for performing these assays. In this chapter we describe the most easily used and robust procedure that is routinely used in our laboratory.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16350414     DOI: 10.1385/1-59259-982-6:411

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  3 in total

1.  A novel intracellular antibody against the E6 oncoprotein impairs growth of human papillomavirus 16-positive tumor cells in mouse models.

Authors:  Carla Amici; Michela Visintin; Francesca Verachi; Francesca Paolini; Zulema Percario; Paola Di Bonito; Angela Mandarino; Elisabetta Affabris; Aldo Venuti; Luisa Accardi
Journal:  Oncotarget       Date:  2016-03-29

2.  Production of functional, stable, unmutated recombinant human papillomavirus E6 oncoprotein: implications for HPV-tumor diagnosis and therapy.

Authors:  Elena Illiano; Olivia Costantina Demurtas; Silvia Massa; Paola Di Bonito; Valerio Consalvi; Roberta Chiaraluce; Carlo Zanotto; Carlo De Giuli Morghen; Antonia Radaelli; Aldo Venuti; Rosella Franconi
Journal:  J Transl Med       Date:  2016-07-28       Impact factor: 5.531

3.  Molecular insights into the interaction of HPV-16 E6 variants against MAGI-1 PDZ1 domain.

Authors:  Lilian Esmeralda Araujo-Arcos; Sarita Montaño; Ciresthel Bello-Rios; Olga Lilia Garibay-Cerdenares; Marco Antonio Leyva-Vázquez; Berenice Illades-Aguiar
Journal:  Sci Rep       Date:  2022-02-03       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.